<DOC>
	<DOCNO>NCT02209051</DOCNO>
	<brief_summary>The primary goal study demonstrate increase rate complete wound closure AMNIOEXCEL® compare routine care patient chronic diabetic foot ulcer</brief_summary>
	<brief_title>Phase IV Study Evaluate Efficacy AMNIOEXCEL Diabetic Foot Ulcers</brief_title>
	<detailed_description>Potential study candidate Screened Inclusion Exclusion criterion provide informed consent . Candidates wound cleanse debrided ( necessary ) , photograph measure . Blood drawn laboratory analysis . Patients return two week later assessment . Upon return , per original protocol , patient would randomize &lt; 20 % closure ; per Amendment 1 , wound close &lt; 30 % area 2 week Screening Period eligibility criterion meet , patient randomize ( 1:1 ) receive either AMNIOEXCEL® Standard Care ( SOC ) SOC alone . All patient enrol study receive SOC . For purpose study , Standard Care ( SOC ) include debridement necrotic/non-viable tissue , moist wound dressing , off-loading ( appropriate , DH Walker ) infection surveillance management . For randomized receive AMNIOEXCEL® , addition SOC , tissue apply wound debrided hemostasis achieve . The wound dress non-adherent dressing ( e.g . Adaptic ) cover moisture retentive dressing . The patient return weekly wound care , photographs ulcer measurement . At visit , wound assess AMNIOEXCEL® reapplied appropriate , base upon physician judgment . All patient complete participation Week 6 . This open label study attempt make blind subject Investigators randomization allocation .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1. ambulatory person least 18 year age time informed consent . 2. type 1 type 2 diabetes mellitus . 3. glycosylated hemoglobin ( HbA1c ) ≤12 % 4. least one wound is/has : Wagner grade 1 superficial 2 ( without bone , tendon joint exposure ) , duration least 1 month , clinical sign infection osteomyelitis , 1cm2 25cm2 area , per original protocol , close &lt; 20 % area Screening Period ; per Amendment # 1 , close &lt; 30 % area Screening located foot , distal malleoli . 5. adequate circulation affect extremity 6. serum creatinine &lt; 3.0mg/dl . 1. participate another clinical trial within 30 day prior consent , 2 . Active Charcot deformity study foot ( i.e . erythematous , warm , edematous actively remodel ) 3. receive radiation chemotherapy kind , 4. know suspected malignancy current ulcer , 5. pregnant breast feeding , 6. active malignant disease , 7. receive hemo peritoneal dialysis , 8. sickle cell anemia Raynaud 's syndrome , 9. diagnosis autoimmune connective tissue disease , 10. receive biologic agent , growth factor , xenograft skin equivalent 30 day prior consent , 11. expose bone , tendon joint capsule study ulcer , 12. currently receive antibiotic ( reason ) , 13. take medication consider immune system modulators .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetic Foot Ulcers</keyword>
	<keyword>AMNIOEXCEL</keyword>
	<keyword>Wagner Grade 1 2 foot ulcer</keyword>
	<keyword>Wound</keyword>
	<keyword>Foot health</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Foot Ulcer</keyword>
	<keyword>Diabetic Foot</keyword>
	<keyword>Foot Diseases</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Leg Ulcer</keyword>
	<keyword>Skin Ulcer</keyword>
	<keyword>Diabetic Angiopathies</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Diabetic Neuropathies</keyword>
</DOC>